Lepu Medical (300003.SZ) plans to invest in the establishment of Huaxia Zhiyuan, a fund dedicated to developing the Alpha-targeted therapy industry chain

Zhitongcaijing · 07/01 10:49

Zhitong Finance App News, Lepu Healthcare (300003.SZ) announced that the company plans to sign the “Huaxia Zhiyuan Venture Capital Fund (Beijing) Partnership (Limited Partnership) Partnership Agreement” with professional investment institutions Huaxia Equity Investment Fund (Beijing) Partnership (Limited Partnership)) and other limited partners to invest in the establishment of a Huaxia Zhiyuan Venture Capital Fund (Beijing) partnership (limited partnership) (the specific name is based on industrial and commercial registration, hereinafter referred to as “Huaxia Zhiyuan”). The total amount of funds pledged out of the fund is RMB 35 million, of which the company pledged RMB 20 million using its own funds. After the establishment of Huaxia Zhiyuan, Huaxia Equity was its general partner/executive partner, and Huaxia Equity acted as the fund manager.

The fund's investment activities are dedicated to developing the Alpha-targeted therapy industry chain and promoting its clinical popularization, with a view to significantly improving the survival status and survival period of cancer patients concerned. The fund will mainly invest in unlisted companies in the entire industry chain, such as biomedicines for molecular diagnosis and targeted therapy and their molecular structures or raw materials, radiopharmaceuticals for molecular diagnosis and targeted alpha therapy and their structures or raw materials, and related professional services.